ARVINAS INC
NASDAQ: ARVN (Arvinas, Inc.)
Last update: 5 hours ago7.74
-0.07 (-0.90%)
| Previous Close | 7.81 |
| Open | 7.82 |
| Volume | 1,164,794 |
| Avg. Volume (3M) | 1,815,319 |
| Market Cap | 568,252,224 |
| Price / Sales | 1.55 |
| Price / Book | 0.960 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -10.92% |
| Operating Margin (TTM) | 37.82% |
| Diluted EPS (TTM) | -0.660 |
| Quarterly Revenue Growth (YOY) | 646.20% |
| Total Debt/Equity (MRQ) | 1.59% |
| Current Ratio (MRQ) | 4.58 |
| Operating Cash Flow (TTM) | -250.70 M |
| Levered Free Cash Flow (TTM) | -2.69 M |
| Return on Assets (TTM) | -5.39% |
| Return on Equity (TTM) | -7.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Arvinas, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.89% |
| % Held by Institutions | 90.98% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Opaleye Management Inc. | 30 Jun 2025 | 1,680,000 |
| New Leaf Venture Partners, L.L.C. | 30 Jun 2025 | 1,585,721 |
| Nextech Invest, Ltd. | 30 Jun 2025 | 1,408,394 |
| Nextech Invest Ltd. | 31 Dec 2024 | 1,408,394 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (HC Wainwright & Co., 132.56%) | Buy |
| Median | 16.00 (106.72%) | |
| Low | 15.00 (Guggenheim, 93.80%) | Buy |
| Average | 16.33 (110.98%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 6.24 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 07 Aug 2025 | 15.00 (93.80%) | Buy | 6.24 |
| HC Wainwright & Co. | 07 Aug 2025 | 18.00 (132.56%) | Buy | 6.24 |
| Wells Fargo | 07 Aug 2025 | 16.00 (106.72%) | Buy | 6.24 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Aug 2025 | Announcement | Arvinas to Participate in Upcoming Investor Conferences |
| 08 Aug 2025 | Announcement | Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer |
| 06 Aug 2025 | Announcement | Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 30 Jul 2025 | Announcement | Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 |
| 09 Jul 2025 | Announcement | Arvinas Announces Retirement of Chief Executive Officer and Succession Plan |
| 13 Jun 2025 | Announcement | Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |